Amantadine
Amantadine is used in veterinary medicine mainly as an adjunct for chronic pain, particularly when central sensitization or a neuropathic component contributes to an inadequate response to conventional analgesics. It is generally combined with an NSAID or another appropriate analgesic rather than relied on as a sole pain medication.
Although originally developed as an antiviral and also used for neurologic disease in people, those human indications do not define its main veterinary role. Historical equine influenza investigations have limited routine clinical applicability and should be distinguished from its pain-modulating use in dogs and cats.
Group
NMDA receptor antagonist; adjunctive analgesic; influenza-A antiviral
Mechanism of Action
Amantadine antagonizes N-methyl-D-aspartate (NMDA) receptor signaling in the central nervous system. Repeated excitatory input through these glutamate-sensitive receptors can amplify pain processing, producing central sensitization, hyperalgesia and allodynia. Reducing this amplification can improve the contribution of other analgesics to a multimodal plan.
Its effect is therefore modulation of pain processing rather than strong immediate blockade of every painful input. It is not a reliable standalone analgesic, and improvement in chronic pain can develop differently from the rapid response expected to an opioid or local anesthetic. NMDA modulation may also influence tolerance to opioid analgesia.
Against susceptible influenza-A strains, amantadine interferes with the viral M2 protein and early replication steps. Dopaminergic enhancement and anticholinergic actions contribute to its wider pharmacology, but they do not establish effectiveness for veterinary Parkinson-like syndromes or routine influenza treatment.
Dose Rates
Dogs
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Chronic pain adjunct — every-24-hour regimen | 3–5 mg/kg | PO | Every 24 h | Do not use in: Pregnancy when avoidable; Use with another appropriate analgesic; includes refractory osteoarthritis and wind-up management. |
| Chronic pain adjunct — every-12-hour regimen | 3–5 mg/kg | PO | Every 12 h | Do not use in: Pregnancy when avoidable; Separate reported schedule; individualize for renal function, tolerance and response. |
Cats
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Chronic pain adjunct — standard reported regimen | 3 mg/kg | PO | Every 24 h | Do not use in: Pregnancy when avoidable; May require a suitable compounded formulation; evaluate response and tolerance closely. |
| Chronic pain adjunct — alternative reported range | 3–5 mg/kg | PO | Every 24 h | Do not use in: Pregnancy when avoidable; The upper end is a separate individualized alternative, not an automatic starting dose. |
Horses
| Use / stage | Dose | Route | Schedule | Instructions |
|---|---|---|---|---|
| Equine influenza-A — historical experimental IV regimen | 5 mg/kg | IV | Every 4 h | Historical equine-2 influenza study regimen; variable exposure and seizure risk limit routine use. Oral preparations must not be used intravenously. |
Indications
- Adjunctive treatment of chronic musculoskeletal pain in dogs, particularly osteoarthritis with incomplete response to an appropriate NSAID-based plan.
- Selected neuropathic or sensitization-associated pain in dogs and cats as part of multimodal analgesia, including cases with exaggerated responses to stimulation.
- Addition to other analgesics when central amplification or opioid tolerance is suspected to contribute to inadequate control; the underlying painful condition still requires treatment.
- Historical experimental treatment of equine influenza-A infection. Variable exposure, resistance and limited clinical evidence prevent this from being a routine first-line equine antiviral indication.
Contraindications
- Avoid in patients with known amantadine hypersensitivity.
- Avoid during pregnancy when possible because high-dose animal studies demonstrate embryo-fetal toxicity.
- Use particular caution with renal impairment, seizure disorders, cardiac dysfunction, hepatic disease or conditions aggravated by anticholinergic effects.
Interactions
- Selegiline and other CNS stimulants may increase excitation; avoid or closely reassess the combination.
- Anticholinergic medicines can increase anticholinergic adverse effects.
- Trimethoprim/sulfonamides, quinidine, quinine, thiazides or triamterene may reduce elimination and increase exposure.
- Urinary acidifiers can increase renal elimination; do not use this interaction to improvise a dosing or overdose-treatment plan.
Adverse effects
- Agitation, anxiety, gastrointestinal upset, loose stools, flatulence or diarrhea can occur, especially early in treatment.
- Dry mouth and other anticholinergic effects are possible; the feline adverse-effect profile is incompletely characterized.
Toxicity
Overdose can cause neurologic excitation, tremors or seizures, cardiac rhythm disturbances and respiratory or renal dysfunction. There is no established specific antidote. Dose-related behavioral effects and serious toxicity have been reported; absence of signs at a previous dose does not establish safety of escalation.
Preparations
| Preparation | Form | Strength | Route |
|---|---|---|---|
| Amantadine hydrochloride immediate-release 100 mg capsule Immediate-release capsule; do not substitute an extended-release formulation by matching the printed strength alone. | Capsule | 100 mg / capsule | PO |
| Amantadine hydrochloride immediate-release 100 mg tablet Immediate-release formulation. | Tablet | 100 mg / tablet | PO |
| Amantadine hydrochloride oral liquid 10 mg/mL Confirm the dispensed concentration and stability; oral use only. | Oral Liquid | 10 mg / mL | PO |
Monitoring and Administration
Use as part of a multimodal analgesic plan rather than substituting it for effective primary analgesia. Improvement may take approximately a week; assess pain, mobility and functional response.
The canine every-12-hour and every-24-hour schedules are distinct published alternatives. Choose one regimen; do not combine them or interpret the interval as an instruction to escalate automatically.
Monitor behavior, gastrointestinal tolerance and renal function when clinically indicated. Renal impairment may require an individualized dose or interval; a universal adjustment has not been established here.
Use the matching immediate-release formulation. Store tablets and capsules tightly closed at room temperature; protect liquid from freezing and follow product storage conditions. Compounded formulations need an established stability and concentration.
The equine IV influenza regimen is retained as a historical reference because response and pharmacokinetics vary and neurologic adverse effects have been reported.
Do not extrapolate human Parkinson-disease or influenza doses to veterinary patients. The US restriction on extra-label influenza-antiviral use in chickens, turkeys and ducks must be observed where applicable.